The ferocious rally in Vertex Pharmaceuticals shares on results in early stage data for its new cystic fibrosis treatment will surely tempt some investors to exit. That may not be wise, though, as the rally is likely to continue.
from WSJ.com: Markets http://ift.tt/2uzwokv
via https://ifttt.com/ IFTTT
No comments:
Post a Comment